Drugs and patents in ATC class N02BG - Other analgesics and antipyretics

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
PRIALT	ziconotide acetate
>Tradename	>Generic Name

Last updated: April 25, 2026

What defines ATC N02BG and what is in the market?

ATC Class N02BG covers “Other analgesics and antipyretics.” Market participants treat this as a residual bucket for analgesic and antipyretic actives that do not fall into the main named subclasses (for example, typical opioid or NSAID categories). In practice, the category clusters around three commercial themes:

Oral, non-opioid pain relief products (often “combination analgesics” or non-traditional analgesics).
Fever and pain products where the active is positioned around acute symptomatic treatment.
Regional “branded exclusivity” strategies in which patents, second-generation formulations, and method-of-use claims carry the majority of value after first approval.

Because N02BG is an ATC bucket rather than a single MoA, the patent landscape is best approached as an active-by-active map. The market dynamics then follow the exclusivity stack for each active rather than a single monograph.

How do market dynamics typically move in N02BG?

Across jurisdictions, N02BG pricing and volume dynamics usually track these drivers:

Competitive structure

Branded-to-generic transition dominates late-stage volume.
OTC vs prescription status changes the speed of erosion. OTC regimes usually see faster substitution after key patents expire.
Channel mix matters: pharmacy counters and supermarket chains amplify generics quickly; hospital procurement slows erosion for products with specific clinical pathways.

Claims and lifecycle mechanics

Value preservation commonly relies on one or more of the following:

Extended release or dosing changes (formulation patents).
Salt/crystal polymorph or hydrate control (solid-state exclusivity).
New combinations (fixed-dose combinations) that shift physician and consumer habits.
Method-of-use (indication expansion or dosing regimen changes).
Packaging or administration (device or regimen patents for combination pain/fever products).

Regulatory and enforcement tempo

Patent linkage regimes (where present) can delay generic entry using Orange Book-style listings or patent dispute mechanisms.
Indication-specific exclusivity (where applicable) can keep branded demand even after broad composition patents fall.
Shorter attrition cycles in symptomatic OTC analgesics compress the time window for enforcement to the early post-expiry years.

Which patent types matter most in N02BG?

N02BG portfolios are typically protected by a layered exclusivity stack:

1) Composition of matter (DoC) patents

Active ingredient and specific chemical forms.
Salt/hydrate/polymorph coverage if the active is disclosed in multiple solid forms.
Broad DoC tends to anchor long-term exclusivity but is less common in late lifecycle “brand reloading” once generics appear.

2) Formulation and delivery patents

Extended-release matrices, coatings, and particle engineering.
Fixed-dose combinations and ratio windows.
Bioavailability and dissolution targets used to support novelty.

3) Method-of-use and dosing regimen patents

Specific pain syndromes or fever presentations (regional label variations).
Dosing schedules and titration methods.
Switch-to-rescue approaches that align with clinical practice guidelines.

4) Process and impurity-control patents

Manufacturing processes that reduce impurities and meet defined specs.
Process patents can still matter if courts or examiners treat them as distinct from DoC.

What does the patent landscape look like across jurisdictions?

N02BG should be evaluated by “event windows,” not single filing dates. Typical windows include:

First approval date window: establishes the baseline for priority and subsequent continuations/divisionals.
Secondary filing window: often 2 to 6 years after first approval for reformulation and combination strategies.
Generic entry pressure window: typically triggered 3 to 8 years after first approval for markets with early generics.
Enforcement and settlements: frequently determine effective market exclusivity more than legal expiration.

Business implication: in N02BG, the “last patent standing” frequently comes from formulation and combination claims, not the originating DoC. That makes freedom-to-operate (FTO) analysis heavily dependent on claim construction and product mapping, not just bibliographic status.

Where are the patent cliffs likely to be?

N02BG patent cliffs usually cluster around:

Expiry of broad DoC on the active or core salt/polymorph.
End of protection for the branded fixed-dose combination ratio or dosing regime.
Last formulation patent expiration for extended release or improved dissolution.

In practical portfolio terms, the biggest cliff risk comes from:

One dominant active with a single broad composition patent, paired with weak secondary protection.
A branded combination where the combination ratio and method-of-use are the main novelty and are narrow.
A polymorph or hydrate that is easy to replicate in alternative crystal forms.

How do companies defend N02BG market position after early losses?

Common defense patterns:

Switch to new solid-state form: brand moves from one polymorph/salt to another with a new formulation line.
Combination re-launch: add another active (often an NSAID or antipyretic co-agent) to maintain brand preference and physician prescribing habits.
Dose regimen modernization: reduce dosing frequency or shift timing (for example, “take with food” or “rescue dosing after X hours”) to generate new method-of-use claims.
Pediatric and geriatric label expansions: where regulators grant specific labeling exclusivities.

What is the most common patent expiry profile in this class?

N02BG typically shows:

A front-loaded DoC, then
a mid-cycle reloading wave (formulations and combinations), then
a late-cycle taper where generics use partial design-arounds (different salts, altered release profiles, alternative ratios).

This yields a market where effective exclusivity is often 2 to 6 years shorter than “paper life” if secondary patents are narrow or difficult to enforce.

Patent landscape structure: how to map N02BG without missing value

For decision-grade mapping, the landscape should be built as:

Product-by-product active listing: each branded and generic product is mapped to its active(s), salt form(s), dosage form, and regimen.
Patent linkage identification: for each market, list relevant patents in patent registers and litigation records.
Claim-type segmentation: separate DoC, formulation, method-of-use, and process patents.
Expiry clustering: identify overlapping expiration dates where a generic launch is most likely.
Design-around pressure test: for each branded product, identify which claim types are easiest for generics to circumvent (salt choice, release profile, ratio changes).

This is the operational approach used to avoid category-bucket errors inherent in ATC residual classes.

What are key takeaways for investors and R&D leaders?

N02BG is not one market. It is a portfolio of analgesic and antipyretic actives that behave like separate exclusivity stories.
Secondary patents drive late-stage value. Formulation, combination ratio, and method-of-use claims more often determine whether the brand retains share after DoC expiry.
Effective exclusivity can compress quickly. Symptomatic analgesics face faster generic substitution, especially when OTC channel rules or label breadth allow switching.
FTO must be claim-type aware. A single DoC expiry date is rarely enough to predict generic feasibility; product-specific mapping to formulation and dosing claims is required.
Design-around risk is high. Salt/polymorph and release profile claims often face near-term circumventability.

Key Takeaways

ATC N02BG is a residual analgesic/antipyretic category where each active and product line follows its own exclusivity and lifecycle path.
Market share erosion accelerates once broad exclusivity ends, because symptomatic and often OTC-facing products convert to generics quickly.
Patent cliffs are driven by narrow secondary claims (combinations, dosing regimens, solid-state forms, and extended-release formulations), not just DoC expiration.
An actionable landscape requires product-to-claim mapping, focusing on claim type and design-around pathways.

FAQs

How should N02BG be analyzed for patents if it is a residual ATC bucket?
By mapping each marketed product to active(s), dosage form, and regimen, then segmenting patents by claim type (DoC, formulation, method-of-use, process) and clustering expirations by product line.
What patent types most often determine effective exclusivity in analgesics?
Formulation and combination claims, plus method-of-use or dosing regimen claims that tie to label-defined regimens.
Why can effective exclusivity be shorter than legal patent life?
Because symptomatic analgesics and antipyretics switch quickly to generics, and narrow secondary claims can be circumvented or invalidated earlier than broad composition claims.
What are the most common generic design-arounds in N02BG-like portfolios?
Alternative salts/polymorphs, altered release profiles, different fixed-dose ratios, and redesigned dosing regimens that avoid specific method-of-use claim elements.
What is the best way to identify likely patent cliffs for N02BG products?
Build expiry clusters by product line across jurisdictions, then overlay claim-type narrowness and design-around likelihood to estimate feasible generic entry timing.

References

[1] World Health Organization. ATC classification system. WHO Collaborating Centre for Drug Statistics Methodology. (Accessed via WHO ATC/DDD structure for N02BG).

Drugs in ATC Class N02BG

Drugs in ATC Class: N02BG - Other analgesics and antipyretics

Market dynamics and patent landscape for ATC Class N02BG: Other analgesics and antipyretics